---
schema_version: "secwatch.filing_event.v1"
accession: "0000784199-23-000014"
form_type: "8-K"
ticker: "AORT"
cik: "0000784199"
company_name: "ARTIVION, INC."
filed_at: "2023-02-16T23:59:59+00:00"
generated_at: "2026-06-19T09:55:42.239679+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Artivion Q4 GAAP EPS $0.05 vs ($0.51) loss; 2023 revenue outlook $331M-$343M

## Summary
- Q4 revenue $79.4M, flat GAAP, +5% constant currency; On-X +11% CC, aortic stent grafts +16% CC.
- GAAP net income $2.2M ($0.05 EPS) vs net loss $20.1M ($0.51); non-GAAP $4.2M ($0.10).
- FY2022 revenue $313.8M (+5% GAAP, +9% CC); net loss $19.2M ($0.48) vs $14.8M ($0.38) in 2021.
- Received CE mark for BioGlue under EU MDR in Q4 2022.
- 2023 guidance: CC revenue growth 8-12%, revenue $331M-$343M, adjusted EBITDA >$50M (+20%).

## SEC filing metadata
- accession: 0000784199-23-000014
- form_type: 8-K
- ticker: AORT
- cik: 0000784199
- company_name: ARTIVION, INC.
- filed_at: 2023-02-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/784199/000078419923000014/0000784199-23-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/784199/000078419923000014/aort-20230216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000784199-23-000014
- JSON: https://secwatch.observer/filing/0000784199-23-000014.json
- Plain text: https://secwatch.observer/filing/0000784199-23-000014.txt

## Key facts
- Earnings Releases
  ARTIVION, INC. reported the fourth quarter ended December 31, 2022 results: revenue $79.4 million, net income $2.2 million, EPS $0.05 per fully diluted common share. Guidance reaffirmed.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $79.4 million
  - Net income: $2.2 million
  - EPS: $0.05 per fully diluted common share
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: Total revenues for the fourth quarter of 2022 were $79.4 million, flat on a GAAP basis and an increase of 5% on a non-GAAP constant currency basis, both compared to the fourth quarter of 2021. Net income for the fourth quarter of 2022 was $2.2 million, or $0.05 per fully diluted common share, compared to net loss of ($20.1) million, or ($0.51) per fully diluted common share for the fourth quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/784199/000078419923000014/0000784199-23-000014-index.htm
- Earnings Releases
  ARTIVION, INC. reported the full year ended December 31, 2022 results: revenue $313.8 million, net income ($19.2) million, EPS ($0.48) per fully diluted common share. Guidance reaffirmed.
  - Period: the full year ended December 31, 2022
  - Revenue: $313.8 million
  - Net income: ($19.2) million
  - EPS: ($0.48) per fully diluted common share
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: Total revenues for 2022 were $313.8 million, reflecting an increase of 5% on a GAAP basis and 9% on a non-GAAP constant currency basis compared to the full year of 2021. Net loss for 2022 was ($19.2) million, or ($0.48) per fully diluted common share, compared to net loss of ($14.8) million, or ($0.38) per fully diluted common share for the full year of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/784199/000078419923000014/0000784199-23-000014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.